Developing and Implementing Performance Outcome Assessments: Evidentiary,Methodologic,and Operational Considerations

Abstract

The use of performance outcome (PerfO) assessments to measure cognitive or physical function in drug trials presents several challenges for both sponsors and regulators, owing in part to a relative lack of scientific guidance on their development, implementation, and interpretation. In December 2016, the Duke-Margolis Center for Health Policy convened a 2-day workshop to explore the evidentiary, methodologic, and operational challenges associated with PerfO measures, and to identify potential paths to addressing these challenges. This paper presents both a summary of the discussion as well as additional input from a working group of experts from FDA, industry, academia, and public-private consortia. It is intended to advance the discussion around the development and use of PerfO measures to assess patient functioning in clinical trials intended to support registration of new treatments, and to highlight the key gaps in knowledge where additional research, collaboration, and discussion are needed.

Keywords

clinical outcome assessment performance outcome assessments concept of interest context of use

Get full access to this article

View all access options for this article.

References

FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD: Food and Drug Administration; Bethesda, MD: National Institutes of Health; 2016. https://www.ncbi.nlm.nih.gov/books/NBK338448/. Accessed September 20, 2017.

Walton

Powers

Hobart

. Clinical outcome assessments: conceptual foundation—report of the ISPOR Clinical Outcomes Assessment—Emerging Good Practices for Outcomes Research Task Force. Value Health. 2015;18:741–752.

World Health Organization. International Classification of Functioning, Disability and Health (ICF). Geneva: World Health Organization; 2001.

United States Food and Drug Administration Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Published 2009. Accessed September 20, 2017.

United States Food and Drug Administration. Wheel and spokes diagram: clinical outcome assessments. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM370175.pdf. Accessed September 20, 2017.

United States Food and Drug Administration. Roadmap to patient-focused outcome measurement in clinical trials. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM370174.pdf. Accessed September 20, 2017.

Delaney

Rudser

Yund

Whitley

Haslett

Shapiro

. Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome. JIMD Rep. 2014;13:129–137.

Shapiro

Bernstein

Adams

. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Mol Genet Metab. 2016;118:65–69.

Kobak

Engelhardt

Williams

JBW

Lipsitz

. Rater training in multicenter clinical trials: issues and recommendations. J Clin Psychopharm. 2004;24:113–117.